Treament News in GIST: EU - Positive opinion for ripretinib in GIST

EMAGood news for GIST patients in the EU: On 16 September 2021, the CHMP (Committee for Medicinal Products for Human Use) of EMA has issued a positive opinion on granting the marketing approval for ripretinib (Qinlock®) for patients with advanced gastrointestinal stromal tumours (GIST) who already received three or more kinase inhibitors prior. Read EMA’s press release here: https://www.ema.europa.eu/en/medicines/human/summaries-opinion/qinlock